No. of Observations by Diagnosis | Total | |||
---|---|---|---|---|
RA | PsA | AS | ||
Total no. of patients | 4938 | 1391 | 753 | 7082 |
Completed visit at 3 mo | 4036 | 1120 | 599 | 5755 |
Answered MCII and PASS | 2898 | 850 | 477 | 4225 |
Additional instrument, % | ||||
EQ-5D | 728 (25) | 250 (29) | 207 (43) | 1185 (28) |
SF-6D | 2771 (96) | 819 (96) | 465 (97) | 4055 (96) |
MHAQ | 2878 (99) | 845 (99) | 474 (99) | 4197 (99) |
Patient global VAS | 2876 (99) | 847 (100) | 474 (99) | 4197 (99) |
Pain VAS | 2872 (99) | 847 (100) | 475 (100) | 4194 (99) |
Treatment type for patients who answered MCII and PASS | ||||
Anti-TNF monotherapy | 251 | 68 | 271 | 590 |
Anti-TNF + MTX | 547 | 134 | 72 | 753 |
MTX monotherapy | 1132 | 428 | 34 | 1594 |
MTX combination | 298 | 43 | 7 | 348 |
Leflunomide | 208 | 70 | 4 | 282 |
Sulfasalazine | 219 | 89 | 71 | 379 |
Other | 243 | 18 | 18 | 279 |
Total | 2898 | 850 | 477 | 4225 |
DMARD: disease-modifying antirheumatic drug; RA: rheumatoid arthritis; PsA: psoriatic arthritis; AS: ankylosing spondylitis; PASS: Patient Acceptable Symptom State; MCII: Minimal Clinically Important Improvement; EQ-5D: EuroQol-5 Dimensions; SF-6D: Short-Form-6 Dimensions; MHAQ: Modified Health Assessment Questionnaire; VAS: visual analog scale; TNF: tumor necrosis factor; MTX: methotrexate.